Mannkind, Game-Chancer in Sachen Diabetik? (Seite 111)

[Magnetfeldfredy]

Gute Liste aus stocktwits.com was wir für Trigger-Points vor uns haben:

StupidShort
04:07 AM
$MNKD
Let me explain further, daily SP is not the main metric to gauge the approach and performance of the CEO. And here are the results of his strategy:
1) TRx - 2017-$15.1M, 2018-$36.4M, 2019 $56.5M increasing sales not decreasing
2) Restructure with reduced debt load
3) Launching of Afrezza in Brazil very soon
4) Partnerships with UTHR
5) Milestone payments from UTHR
6) Tre-T study completion 2H20
7) Pediatric trial completion 2H20
8) Filing of NDA for Tre-T 2H20
9) Upcoming Tre-T milestone payments from UTHR
10) Payments from Cipla
11) Approval in India and Australia 2020/2021

Focusing of SP for approach and performance? Wrong!!

[Magnetfeldfredy]

Prominente Empfehlungsliste mit Mannkind:

232 viewsJan 3, 2020, 09:20am
7 Hot Drug Stocks To Buy In 2020
MoneyShow Contributor
MoneyShow
Contributor Group
Markets

Each year, MoneyShow surveys the nation’s most respected and well-known newsletter advisors for their favorite investment ideas for the coming year. From conservative quality blue chips for safe and steady returns to high-growth stocks with massive potential upside, MoneyShow's Top Picks Report features 100+ investment ideas covering the best stocks and ETFs to buy for 2020.

Here are seven favorites from the pharmaceutical and biotechnology space.
Off The Charts M A

FILE- In this Jan. 3, 2019, file photo specialist Peter Giacchi, right, calls out prices for ... [+]ASSOCIATED PRESS

Mike Larson, Safe Money Report

The biotechnology company Amgen (AMGN) — my more speculative favorite for 2020 — sells several different medical treatments. The firms products include the infection-fighting drug Neulasta, migraine treatment Aimovig, cholesterol drug Repatha, rheumatoid arthritis drug Enbrel and kidney therapy Sensipar. Enbrel is its biggest seller, at approximately 25% of sales, followed by Neulasta at 13%.
Today In: Money

Amgen has also been active on the M&A front. It recently acquired the rights to Celgene’s Otezla psoriasis drug for $13.4 billion. That product generated around $1.6 billion in sales last year.

Plus, Amgen announced plans to invest $2.7 billion for a 20.5% stake in the Chinese biotechnology firm BeiGene (BGNE). The deal will give Amgen’s cancer drugs greater exposure to the Chinese market. This will also allow the firm to profit if BeiGene’s pipeline of molecularly targeted and immuno-oncology products prove to be effective and ready for commercialization.

PROMOTED
Civic Nation BrandVoice
| Paid Program
Not Another Student Loan Piece
UNICEF USA BrandVoice
| Paid Program
Want To Know What Matters Most To Kids? Ask The Experts.
Grads of Life BrandVoice
| Paid Program
5 Myths About High School Interns (And Why You Should Hire Them)

Amgen pays a generous quarterly dividend of $1.45 per share. That was good for an indicated yield of 2.7% in December 2019. Further, the shares broke out to a fresh all-time high on heavy volume late last year. And it goes without saying that biotechnology is not an industry affected by the vicissitudes of the U.S. economy. That makes this promising, relatively defensive pharma play a great addition to investor portfolios.

Kelley Wright, Investment Quality Trends

AbbVie, Inc. (ABBV) is a global, research-based biopharmaceutical company; its products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and HIV.

The company is also involved in neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; as well as other serious health conditions.

The firm also has a pipeline of promising new medicines in clinical development across such important medical specialties as immunology, oncology and neuroscience, with additional targeted investment in cystic fibrosis and women's health.

In June 2019, AbbVie entered into a definitive transaction agreement to acquire Allergan plc (AGN). The transaction is expected to close in early 2020 and would create a massive biopharmaceutical company with about $48 billion in combined 2019 revenue.

Management expects that shareholders will see 10% EPS accretion in the first full year of the combination and that the company can achieve annual pre-tax synergies and other cost reductions of over $2 billion by year 3.

The company’s combined net debt of approximately $95 billion will be reduced by $15 to $18 billion by 2021-end, while continuing to support dividend growth and pipeline investment. Historically the shares offer good value when the dividend yield is 4.50%. Based on the current dividend of $4.72 per share, a 4.50% dividend is realized at $105 per share. Trading recently around $88 per share, the stock is about a 20% discount from its historically repetitive area of high yield.

Tom Bishop, BI Research

Anavex (AVXL) is a bio-pharmaceutical company that amazingly few know about, but those who do are passionate about. Its lead drug is Anavex 2-73 (A2-73), an orally available drug with a clean safety profile that gives every indication so far of being highly effective against Alzheimer’s disease.

I’ll explain. Though there are 4 drugs approved, none of them really works beyond 6 months. It is currently in a 1-year, 450-patient Phase 2b/3 Alzheimer’s trial that is halfway through enrollment. If successful the company will file for provisional approval.

In an earlier, smaller Phase 2 study, comparable patients in the ADNI data base not taking Anavex 2-73 saw 4 times the deterioration in their Activities of Daily Living (ADL) scores as those protected by the higher dosage of Anavex 2-73 after two years.

In Anavex’s Phase 2a trial the high dosage of A2-73 cohort saw only a 3-point decline in ADL score (a normal score is about 70 or better) as compared to a 25 point decline (8 times the decline) in the low dosage group (that basically did not work so was effectively a placebo) at 148 weeks.

Same story with the Mini Mental State Exam (MMSE) score (perfect is 30, in this realm scores run below 26) where those taking the higher dose of Anavex 2-73 saw a drop of 1.1 in the MMSE score over two years vs. a drop of 4.4 in untreated patients.

This is phenomenal. Nothing on the market today can come even close to this and if the company can prove this in the Australian trial it will be on track to become the lead Alzheimer’s drug in a market that is at least $10 billion worldwide.

Proof of the pudding, 94% of those who have completed the current 1-year trial period are voluntarily continuing to take A2-73, and some (from the earlier Phase 2a trial) have continued for as much as 3 to 4 more years now. Sometimes that speaks louder than the hard data.

In addition, Anavex is currently wrapping up a Phase 2, 120-patient study with A2-73 for Parkinson’s dementia and is working on three Phase 2 trials for Rett Syndrome, a devastating disease that strikes girls in infancy handicapping them severely in almost every function.

Data from these trials are expected in 2020. I could go on for pages. There are no guarantees on Wall Street, but I hope you will agree that the above at least stacks the odds in our favor.

Chuck Carlson, DRIP Investor

Bristol-Myers Squibb (BMY) is a shining example of value and a top pick for total return. Bristol-Myers Squibb has a number of factors in its favor, not the least of which is solid revenue and earnings growth potential over the next 12 months, an attractive dividend yield of nearly 3%, and a potential kicker in its recent acquisition of Celgene.

Bristol-Myers Squibb is a leading provider of pharmaceuticals. Leading brands include Opdivo, Eliquis, Plavix, Orencia, and Yervoy. Revenues will grow sharply with the addition of Celgene. The addition of Celgene will push annual revenues over $40 billion and give the combined company the number one position in oncology and cardiovascular drugs.

Bristol-Myers Squibb shares trade for just 10 times the 2020 earnings estimate, so investors aren’t paying much for the expected growth. The company is taking on a big chunk of debt to pay for the Celgene deal. Despite the increased debt load, the company just raised its dividend approximately 10%, indicating the firm is fairly confident in its future.

The stock traded in the low $70s in 2018 and was a $77 stock as recently as 2016. I think expected appreciation in the 10%-15% range plus a nearly 3% dividend yield sets up for a nice total return in 2020. I expect these shares to outperform the market over the next year. Please note Bristol-Myers Squibb offers a direct-purchase plan whereby any investor may buy the first share and every share directly from the company.

Mike Cintolo, Cabot Growth Investor

Vertex Pharmaceuticals (VRTX) is a great company, and after a couple of years of choppy action, it appears the buyers are finally beginning to flex their muscles. The company has made hay with cystic fibrosis (CF) treatments, with approvals of individual drugs (it has three on the market today) and combination therapies gradually expanding the share of the CF market it addresses—sales growth has been steady and earnings are following the same upward path.

But what’s brought in the buyers was news that the FDA approved (five months early) Vertex’s triple combination CF treatment — long story short, the combo will greatly expand the number of CF patients the company can serve, and the selling price it’s targeting was higher than many analysts expected.

Bottom line, management hiked revenue guidance after the approval (now looking for a 22% bump in revenues in 2019) and analysts are looking for a very solid 2020 (sales up 26%, earnings up 39%) as the triple combo product gains acceptance, with another round of excellent growth in 2021. All told, earnings are expected to basically double from 2019 to 2021.

The firm has some other early-stage research going on — it eventually wants to diversify away from just CF products — but there’s no question the cystic fibrosis business is going to drive perception in the quarters ahead. Technically, the stock broke out of a two-year dead period in October and looks like it is going to be one of the stock market’s liquid leaders for 2020.

Nate Pile, Nate's Notes

MannKind (MNKD) has a proprietary drug delivery platform called Technosphere that allows it to deliver a wide variety of drugs to the body through the lungs rather than via pills or injections (thus allowing for an often much faster onset of action).

The company's lead product is Afrezza (inhalable insulin), and it is already approved by the FDA for use by both type 1 and type 2 diabetics. Though still quite small relative other mealtime insulins, sales of Afrezza have been growing steadily for the past couple of years,

Doctors need to see results in a small group of patients before they'll start expanding use of the new therapy into the rest of their practice, and the reality is that this "trial" period often takes 12-18 months when it comes to managing diabetes.

And, given the manner in which new ways of managing diabetes have been adopted in the past, I believe the odds are good that 2020 will be the year that Afrezza finally starts to gain some meaningful traction in the marketplace.

Along with Afrezza, MannKind is also developing a Technosphere-based version of treprostinil (along with another undisclosed molecule) with its partner United Therapeutics (UTHR). It also has an agreement in place with privately-held Receptor Life Sciences (RLS) under which RLS is developing cannabis-based products utilizing the Technosphere platform.

And though they are not yet licensed to partners, MannKind is also working on inhalable versions of a number of interesting compounds, most notably epinephrine (for anaphylactic shock), sumatriptan (migraines), and tadalafil (erectile dysfunction).

Thanks to a very aggressive group of short sellers who have flooded the market with 40 million "extra" shares over the years, MannKind's market cap has been beaten down just over half of what it was when the company first came public back in 2004. While it remains to be seen how things will actually play I do find it encouraging that all of those short sales represent pent up buying demand when short sellers eventually close out their trades.

Dr. Joe Duarte, In the Money Options

I’ve liked the action in "Big Pharma" for some time; in my view, pharmaceutical giant Pfizer (PFE) has very positive potential for the new year, New drugs are finally coming on line and hitting revenue and earnings streams and because there are more of them likely to come in what seem to be increasingly encouraging pipelines throughout the sector.

Pfizer lost patent exclusivity for its blockbuster nerve pain drug Lyrica and the stock tanked. But the stock has quietly made a comeback in late 2019 due to its market dominance for blood thinners with Eliquis, its blockbuster cancer drug Inlyta, a broadening set of indications for Xtandi, its prostate cancer treatment, and steady performance for its arthritis drug Xeljans which has recently won extended FDA approval for treatment indications in ulcerative colitis.

Moreover, Pfizer may be sitting on a couple of stealth blockbusters. One is Vyndaquel which treats what used to be considered a rare form of heart failure which may be a more common ailment than previously known and which insurance companies are actually paying for without too much trouble leading to initial sales being well above expectations.

The other potential blockbuster is in a partnership with Eli Lilly (LLY) has the potential to reduce opioid use significantly in the treatment of low back pain. The drug, Tanezumab, is a monoclonal antibody that blocks a substance called nerve growth factor, which has been found to be a key component in spine pain.

If this medication is approved, there is no major competition. And if it is effective, it will likely change the whole chronic pain industry. The drawback is related to a statistically significant potential for users to have damage to bones while under treatment.

There is still room for gains in the healthcare sector and I expect that barring a major market event, the stocks that have lagged in 2019 could be upside surprises in 2020. The Big Pharma stocks are starting to gather steam but there is still time to buy them before they take off.

Click here for access to MoneyShow's 100+ page Top Picks Report featuring the nation’s most respected and well-known newsletter advisors favorite investment ideas for 2020.
Follow me on Twitter or LinkedIn. Check out some of my other work here.
MoneyShow
MoneyShow

MoneyShow — an industry pioneer in investor education since 1981 — is a global, financial media company, operating the world's leading investment and trading conference...

Print
Site Feedback
Tips
Corrections
Reprints & Permissions
Terms
Privacy

©2020 Forbes Media LLC. All Rights Reserved.
AdChoices

Current Time 0:03
/
Duration 1:08


Google Cloud AI Solutions
Google Cloud AI Solutions
BRANDVOICE | Paid Program
Leadership

W
hile artificial intelligence (AI) has been around for many years, deployment has been picking up. Between 2017 and 2018, consulting firm McKinsey & Co. found the percentage of companies embedding at least one AI capability in their business processes more than doubled to 47 percent from 20 percent the year before.

Although companies are adopting it, they often lack a clear plan: A recent IDC survey found that of the companies already using AI, only 25 percent had an enterprise-wide strategy on how to implement it.

To help navigate that challenge, here’s how the four pillars of Google Cloud’s Deployed AI vision can reshape your business.



For AI to be deployed effectively, it must be focused on a new business problem or unrealized opportunity. To that end, there are several areas of business that the technology is well-suited to address.

One key problem is fixing aging processes, notes Ritu Jyoti, program vice president of Artificial Intelligence Strategies for research firm IDC.

“Companies that have been around for a long time will have a lot of archaic processes, and they need to be upgraded,” Jyoti says.

Bank fraud is one prominent example. Machine learning (ML), a subset of AI, provides an opportunity to solve this problem—by helping banks sort through large amounts of bank transactions to detect suspicious patterns of financial activity.

Customer relationships is another area AI can improve. Chatbots, for example, are enhancing customer service by providing support 24/7, Jyoti says. Furthermore, companies can also use AI to develop the right incentives for customers without losing money. Firms sometimes lose income due to lapsed contracts or “stuck deals” in which a transaction is started but unable to be completed, Jyoti notes.

“This feature helps organizations optimize early payment discount offers by using ML algorithms to find the right balance between incentivizing customers while ensuring profitability for the seller,” Jyoti says.

Another business problem in which AI can help is in document processing, including insurance claims, tax returns and mortgage applications, which can involve hundreds of pages of documents on income and assets, notes Vinod Valloppillil, Google’s head of product for Google Cloud Language AI, who spoke at Forbes’ CIO Next conference.

“[Document processing] is one of the few domains that actually brings in multiple parts of AI all simultaneously,” Valloppillil says. It incorporates computer vision, deep learning and natural language processing.




When deploying AI to solve a business problem, the technology should be central to that solution. Many examples across industries—including healthcare and energy—exemplify how innovative problem-solving can hinge on AI.

The medical industry, for instance, is turning to AI to build algorithms to detect pneumonia. With genomic data bringing insights on who will be susceptible to various disease conditions, disease prevention is one area that can’t be solved without AI. An AI platform can also become part of an end-to-end solution when hospitals need to connect medical data to cloud platforms.

AI can also help physicians determine whether a patient has diabetic retinopathy, Valloppillil says. An “Explainable AI” model would help determine if screening was necessary based on the appearance of various regions of the image.

“We’re getting to the point where AI can do quite a bit of engineering,” Valloppillil says.Meanwhile, the energy sector has found AI to be essential to keeping wind facilities “safer, faster, and more accurate,” according to Andrés Gluski, president and CEO of AES, a global power company. Drones and Cloud AutoML Vision, a platform that provides advanced visual intelligence and custom ML models, make these improvements in wind energy possible.



Once you’ve identified the business problem and decided to use AI in the solution, the next step is building customer trust and maintaining proper ethics. In a Deloitte survey of 1,100 IT and “line-of-business” executives, 32 percent placed ethical risks in the top three of AI-related concerns.

To build trust, ethics should come ahead of any productivity or financial gains from using AI. A crucial part of that is being transparent about how a company uses AI.Consulting firm Capgemini recommends using opt-in forms to help build transparency with customers regarding AI. Meanwhile, privacy laws like the European Union’s General Data Protection Regulation (GDPR) also contribute to the transparency requirements for AI.

Jyoti also recommends including fact sheets—similar to how food packaging includes nutrition information—about details like data sources and lineage. A set of AI Principles from Google help businesses ensure that they’re using AI in a responsible manner and that they understand the limits of the technology. Users of AI should maintain accountability to human direction, uphold standards set by scientists and test for safety.

“These are the principles we as a company orient around, things like ‘always optimize around the fairness of AI, and try to avoid any situation where AI can get abused,” Valloppillil says.





Finally, to ensure a cycle of improvement, companies should use clear, objective metrics to assess progress towards their business goals.

For example, if AI is used to assist with résumé screening in the hiring process, make sure the screening adheres to company policies on equal opportunity to maintain fairness. To form an objective metric, come up with representative numbers of candidates for various demographics and train ML algorithms accordingly.

“Avoid the blinders of the homogenous teams,” Jyoti says.Tools and frameworks like Explainable AI can help companies build inclusive systems that address bias, which involves the data not being representative of the decisions a business is trying to make. This makes the problem of “garbage in, garbage out” multiplied a hundredfold, Valloppillil says.

The concept of “explainability” helps provide insight into the decisions that AI helps deliver.

“With explainability we're now finally getting to the point where we go peek inside the box,” Valloppillil says. “We actually have a shot at understanding exactly why does AI make the call.”


looking ahead

As AI continues to evolve, there are increasing opportunities for the technology to meaningfully improve business operations. With ethical implications in mind and a clear focus on measurable metrics, Deployed AI is poised for growth.
Google Cloud AI Solutions
Google Cloud AI Solutions

Google Cloud is widely recognized as a global leader in delivering a secure, open, and intelligent enterprise cloud platform. We’re focused on building solutions in five...

Print
Site Feedback
Tips
Corrections
Reprints & Permissions
Terms
Privacy

©2020 Forbes Media LLC. All Rights Reserved.
AdChoices

Cookie Preference

[Magnetfeldfredy]

Für eine 3-tage und Feiertagswoche ok!

[Kleingeldinvestor]

Week ending Dec 27th.
Trxs 673
Nrx 277
Rrx 396
Sales $1.22m

[pegasusorion]

Denke, nachdem das Ganze mit der E-Zigarette jetzt geklärt scheint sollte die Unsicherheit vorbei sein oder??

[price-of-success]

Afrezza ist überhaupt gut für typ 2

Als zugabe statt der eckeligen spritzen

[price-of-success]

Antwort auf Beitrag Nr.: 62.234.141 von Kleingeldinvestor am 27.12.19 10:36:39

Leute

mega geil- über 900 TRX.was hat das gedauert, diese Hürde zu nehmen

sehr gut

schönes neues Jahr 2020 allen

[Magnetfeldfredy]

Das ist nicht so einfach, Anfang des Jahres werden die neu zu verhandelnden Versicherungsabdeckungen immer wieder für anfängliche Rückschläge führen, aber mittel bis langfristig wird sich Afrezza als schnelllstes und bestes Mealtime-Insulin durchsetzen, wenige Hypos damit weniger Komplikationen, und Kinder hassen Spritzen!
Daneben das tolle UTHR-Programm......., yes we hope!

[Kleingeldinvestor]

Antwort auf Beitrag Nr.: 62.234.366 von Magnetfeldfredy am 27.12.19 11:21:45

Danke fürs posten....
dann dürften die 1000 schnell Geschichte sein

[Magnetfeldfredy]

Ja, Mannkind sucht 19 neue Vertriebler:

Es werden 19 von 19 Stellenangeboten angezeigt
Territory Business Manager (Boston, MA)
23. Dez. 2019
Sales
TERRI01013
Vollzeit
Boston, MA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Boston, MA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Worcester, MA)
23. Dez. 2019
Sales
TERRI01014
Vollzeit
Worcester, MA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Worcester, MA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Hartford, CT)
23. Dez. 2019
Sales
TERRI01015
Vollzeit
Hartford, CT, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Hartford, CT. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Stamford, CT)
23. Dez. 2019
Sales
TERRI01016
Vollzeit
Stamford, CT, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Stamford, CT. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Norfolk, VA)
23. Dez. 2019
Sales
TERRI01017
Vollzeit
Norfolk, VA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Norfolk, VA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Richmond, VA)
23. Dez. 2019
Sales
TERRI01018
Vollzeit
Richmond, VA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Richmond, VA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Morgantown, WV)
23. Dez. 2019
Sales
TERRI01019
Vollzeit
Morgantown, WV, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Morgantown, WV. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Minneapolis, MN)
23. Dez. 2019
Sales
TERRI01020
Vollzeit
Minneapolis, MN, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Minneapolis, MN. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Jackson, MS)
23. Dez. 2019
Sales
TERRI01021
Vollzeit
Jackson, MS, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Jackson, MS. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (New Orleans/Baton Rouge, LA)
23. Dez. 2019
Sales
TERRI01022
Vollzeit
New Orleans, LA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in New Orleans/Baton Rouge, LA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Houston-Central, TX)
23. Dez. 2019
Sales
TERRI01023
Vollzeit
Houston, TX, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Houston-Central, TX. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Portland, OR)
23. Dez. 2019
Sales
TERRI01024
Vollzeit
Portland, OR, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Portland, OR. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Seattle, WA)
23. Dez. 2019
Sales
TERRI01025
Vollzeit
Seattle, WA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Seattle, WA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Oklahoma City, OK)
23. Dez. 2019
Sales
TERRI01026
Vollzeit
Oklahoma City, OK, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Oklahoma City, OK. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
District Business Manager (New England)
23. Dez. 2019
Sales
DISTR01027
Vollzeit
Remote
MannKind Corporation is currently seeking a District Business Manager for the New England area. In this position the incumbent will be responsible for development and management of a district with the goal of maximizing sales to achieving established revenue and profit goals. Strong people leadership and a commitment to developing people is key to the role. Lead, direct and manage the customer activities of sales representatives within a geographic area. Manage expenses in a fiscally responsible manner. Participate in national, regional, and local strategic meetings as well as lead meetings with respective team.
Territory Business Manager (Orlando/Melbourne, FL)
14. Okt. 2019
Sales
TERRI01010
Vollzeit
Melbourne, FL, USA
+1 weitere
We have an exciting opportunity available for a Territory Business Manager (TBM) in Orlando/Melbourne, FL. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Corporate Controller
10. Okt. 2019
Finance/Accounting
CORPO01009
Vollzeit
Westlake Village, CA, USA
The Corporate Controller reports to the Chief Financial Officer and plans, develops, and implements financial and accounting systems, controls, and standards for the entire company. This person will ensure timely production of financial and statistical reports for senior management use and will provide leadership and direction to the accounting department.
Territory Business Manager (Salt Lake City, UT)
19. Sep. 2019
Sales
TERRI01005
Vollzeit
Salt Lake City, UT, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Salt Lake City, UT. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Pittsburgh, PA)
19. Sep. 2019
Sales
TERRI01003
Vollzeit
Pittsburgh, PA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Pittsburgh, PA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Entdecken Sie Ihr Potenzial

Wir helfen Ihnen bei der Erstellung eines Profils, mit dem Sie Ihre Ergebnisse speichern und die relevantesten Stellen finden können.
1 Meine ideale Stellenbezeichnung ist...
2 Mein Ausbildungsniveau ist...
3 Ich besitze eine Lizenz oder Zertifizierung für...
MannKind Corp